Tempest Therapeutics, Inc.(TPST)Stock Analysis

TPST Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Tempest Therapeutics, Inc. (TPST), a Healthcare sector company. TPST is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), Tempest Therapeutics, Inc. reports net income of $-27.7M, free cash flow of $-7.6M. Top institutional holders of TPST by reported 13-F value include Versant Venture Management,, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. TPST trades on the Nasdaq exchange and files with the SEC under CIK 1544227. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TPST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Tempest Therapeutics, Inc. directly from SEC EDGAR.